Close Menu

NEW YORK – Liquid biopsy firm Inivata said today that it is launching a prospective clinical study with France's Centre Léon Bérard cancer center to test whether its InVisionFirst-Lung test can get patients on appropriate treatment more quickly than tissue-based genetic testing.

The randomized Phase III interventional trial is called LIquid Biopsy for the Early detection of LUng cancer LEsion (LIBELULE). Investigators plan to enroll at least 286 patients across 17 clinical sites in France.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Despite differences in their migration habits, eastern and western monarch butterflies are genetically similar, according to a study in Molecular Ecology.

The UK is implementing COVID-19 testing with a 90-minute turnaround time.

The Chan Zuckerberg Biohub is working with California's health department to sequence viral samples from COVID-19 patients to trace viral introductions, according to the San Francisco Chronicle.

In PLOS this week: identification of fungal species in subcutaneous infections, sequencing of Campylobacter found in raw meat from retail stores, and more.